PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry - Based on its recent analysis of the drug discovery technologies market, Frost & Sullivan recognizes Life Technologies with the 2009 North American Frost & Sullivan Company of the Year Award
Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2009/03/24 - Based on its recent analysis of the drug discovery technologies market, Frost & Sullivan recognizes Life Technologies with the 2009 North American Frost & Sullivan Company of the Year Award.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The company's size, product portfolio breadth, market segment leadership, and strong future potential set it apart from any competitor in the life science research tools industry. Moreover, Life Technologies shows great commitment to providing innovative and enabling tools across the life science research continuum.

Formed from the combination of Invitrogen and Applied Biosystems, Life Technologies is on a clear path to become its own unique organization with unparalleled efficiency and speed of operation. More importantly, the reengineered Life Technologies promises extraordinary revenue growth that far outpaces the performance of its two predecessor companies.

"Prior to the 2008 merger, Applied Biosystems held the largest percentage of market share in the microRNA, PCR reagents, capillary electrophoresis sequencing, qRT-PCR, and life sciences mass spectrometry markets, while Invitrogen held the largest percentage of market share in the cell culture and protein expression and purification markets," explains Jonathan Witonsky, Industry Manager, Drug Discovery & Clinical Diagnostics, Frost & Sullivan. "By merging, the new company, Life Technologies, holds a significant market share in nine additional market segments, including the nucleic acid purification and isolation market, the laboratory information management systems market, the cell-based assays market, the research ELISA market, the high content screening market, the liquid chromatography market, the protein electrophoresis market, the RNAi market, and the proteomics array market."

Life Technologies offers approximately 50,000 products and lays claim to an incredibly strong technological foundation of approximately 3,600 patents and licenses. Today, with the Invitrogen and Applied Biosystems brands, Life Technologies is at the forefront of scientific leadership not only with exceptional products and services but also with name recognition and visibility that is not found elsewhere in the industry. The Invitrogen brand will remain platform agnostic with reagents that provide accurate and consistent results on virtually any platform technology. The Applied Biosystems brand will be workflow-centric with integrated, validated, and certified combinations of reagents, instrumentation systems, and services. Together, the two brands will serve the needs of a complex and fast-moving base of approximately 75,000 customers.

Life Technologies generated revenues totaling over $3 billion in 2008. In addition, it generated approximately $500 million in revenues from its joint venture in the mass spectrometry systems business. The company had more than $700 million in revenues from its cell systems business, approximately $900 million in revenues from its genetic systems business, and an estimated $1.4 billion in revenues from its molecular biology systems business. Of even greater significance is the company's unprecedented 27 percent share of the aggregate market segment analyses presented above.

Life Technologies' has an unrivaled scale and financial strength. A $300 million investment in research and development is likely to expand the company's position in the burgeoning markets surrounding advanced genomics, regenerative medicine, diagnostics, forensics, and environmental testing. For example, Life Technologies is building on its leading position in the capillary electrophoresis sequencing market by making a major play in next generation sequencing. By leveraging its Invitrogen brand of nucleic acid sample preparation technologies and Applied Biosystems brand SOLiD™ System for ultra-high throughput DNA sequencing, Life Technologies is expected to have a major role in bringing next generation sequencing to the medical realm.

In the near term, Life Technologies' greatest advantage is the company's ability to exploit its leadership position in four broad technology groups. Specifically, Life Technologies is able to offer customers complete and integrated workflow solutions that can be incorporated throughout a research endeavor. The company is well-positioned to offer customers end-to-end solutions that can bring them from early discovery to clinical application. The world's premier scientists will be able to rely on one provider – Life Technologies – for all of their life science research tools needs.

For the company's rapid success at bringing together Invitrogen and Applied Biosystems, and then reengineering the combination into a whole new organization with vast growth potential, Frost & Sullivan is pleased to present the 2009 Company of the Year Award in the drug discovery technologies market to Life Technologies.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of business development, competitive strategy, customer satisfaction, and leadership within a particular Frost & Sullivan Industry Research Group (IRG). This award recognizes outstanding management, consistent growth, and the ability to offer high quality products and/or services as well as have a positive social and economic impact on local and national communities. It also highlights exceptional customer service offerings and the expertise to take advantage of market changes by capturing and solidifying market presence, or execute of innovative strategies within the existing competitive landscape.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies (lifetechnologies.com) was created by the combination of Invitrogen Corporation and Applied Biosystems Inc.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Jake Wengroff 
210.247.3806 jake.wengroff[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)